Biosimilars are expected to drive significant cost savings for healthcare systems, yet there are many considerations that will affect the View product.
$5,000.00
This analysis covers trends in alliance and mergers and acquisitions (M&A) agreements by Datamonitor Healthcare’s Mid Pharma peer set from View product.
$5,000.00
Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D View product.
$5,000.00
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of View product.
$5,000.00
The route to a formal US regulatory pathway for biosimilar approval was established with the creation of the Biologics Price View product.
$7,500.00
Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
$5,000.00
Ongoing pressures on drug pricing and reimbursement mean that current research and development (R&D) economics are unsustainable. The process of View product.
$5,000.00
The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments View product.
$5,000.00
A range of disorders, some of which share similar underlying pathologies, can affect the retina and lead to progressively worsening View product.
$22,000.00
As the patent cliff for many blockbuster biologic therapies is approaching, clinical development programs for biosimilar options to those therapies View product.
$10,000.00
Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marketers.
$7,500.00
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that could View product.
$7,500.00
Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making.
$7,500.00
In this report, we cover catalysts from 9 devices expected to occur in Q4 2017, along with an overview of View product.
$4,750.00
With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise View product.
$699.00
This Market Spotlight report covers the amyloidosis market, comprising key marketed and pipeline drugs, key upcoming events, patent information, a View product.
$16,500.00
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key pipeline and marketed drugs, clinical trials, upcoming View product.
$16,500.00
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed and pipeline drugs, clinical trials, patent View product.
$16,500.00
In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood View product.
$4,750.00